Medical Analysis

Understanding the Friend Leukemia Integration 1 (FLI1) Transcription Factor: Genomics and Pathology

The Friend leukemia integration 1 transcription factor (FLI1), which is also recognized in scientific literature as transcription factor ERGB, represents a critical protein in humans [3, 8]. This protein is encoded by the FLI1 gene, which is classified as a proto-oncogene [13]. FLI1 belongs to the extensive ETS transcription factor family and is fundamentally implicated in the etiology of virally-induced leukemia, specifically Erythroleukemia [3, 4, 13]. Within this complex biological framework, the ETS-related gene (ERG) functions as a notable member of the E-26 transformation-specific (ETS) family of transcription factors [10, 13]. These factors are essential contributors to diverse developmental processes, which include, but are not limited to, vasculogenesis, angiogenesis, haematopoiesis, and the intricate mechanisms of bone development [3, 4, 10].

Mechanisms and Clinical Significance of FLI1 in Oncology and Hematology

The role of the FLI1 gene extends deep into the mechanisms of tumorigenesis [1, 7]. Specifically, mutations involving the FLI1 gene are known to cause a particular type of aggressive cancerous tumor identified as Ewing sarcoma [1, 7, 12]. Beyond its role in pathology, FLI1 plays a vital and multifaceted role in the maintenance and differentiation of hematopoietic stem cells, as well as in the physiological process of angiogenesis [3, 4, 10].

The clinical implications of FLI1 are wide-ranging, as detailed in the following analysis of its impact across various clinical contexts:

Furthermore, the prognostic significance of FLI1 is substantial. Research indicates that the overexpression of FLI1 in astrocytoma is related to a poor prognosis [9]. Similarly, overexpression of this factor in non-small cell lung cancer (NSCLC) and endometrial cancer is also clinically correlated with a poorer prognosis for the patient [6].

Advanced Diagnostic Methods: Immunohistochemistry and Marker Interpretation

The reliable identification of FLI1 expression relies on precise laboratory methodologies, primarily immunohistochemistry [10]. For this diagnostic test, pathologists utilize formalin-fixed tissue that has been embedded in a paraffin block. When interpreting FLI1 as an immunohistochemical (IHC) marker, there are specific protocols to follow:

• The marker produces nuclear staining [10].

• Endothelial cells serve as an essential positive internal control for the assay [10].

• Even if only 10% of the cells show positivity, it is considered sufficient to label the tissue as Positive [10].

The following table categorizes the IHC marker results for FLI1 across different diagnostic outcomes [5, 10]:

In modern pathology, FLI1 serves as a gold standard for diagnosing angiosarcoma and other tumors of vascular origin [5, 10]. It is also an indispensable tool for identifying tumors that exhibit signs of vascular invasion [10].

Future Horizons: Targeted Therapy and Immunotherapy

As our understanding of tumor biology advances, so too does our ability to intervene therapeutically [11]. ILIRAP, which is a direct target of EWS-FLI1, is highly expressed in Ewing sarcoma (EwS) but is only minimally expressed in normal human tissues [11]. This biological discrepancy makes ILIRAP a promising surface target for medical intervention [11]. Consequently, this target is becoming potentially exploitable for immunotherapy, offering a new frontier in the treatment of cancers driven by FLI1 dysregulation [2, 11].

For Non-Medicos: A Simple Guide to FLI1

What is FLI1?

Think of FLI1 as a biological “master switch” inside your cells [8]. It is a protein that helps control how your body builds blood vessels and produces healthy blood cells [3, 4]. When this switch works correctly, your body stays in balance. However, when the gene responsible for this protein becomes mutated or damaged, it can contribute to the development of serious diseases, including certain types of bone and blood cancers [1, 7].

Why Do Doctors Test For It?

Doctors look for FLI1 using a test called Immunohistochemistry (IHC) [10]. By examining tissue samples under a microscope, they can see if FLI1 is present in the nucleus of your cells [10]. This test is crucial because it acts like a “fingerprint” for specific tumors, such as Ewing sarcoma and vascular tumors (cancers involving blood vessels) [5, 10]. If the test shows that FLI1 is active, it helps doctors confirm a diagnosis and determine the best treatment path [1, 10, 12].

What Does the Result Mean?

• Positive Result: If the test is positive, it means the FLI1 marker is present. This is a very helpful diagnostic clue for doctors when identifying specific types of cancer [10].

• Prognosis: In some cancers, such as those in the brain or lungs, having too much of this protein (overexpression) can suggest that the cancer might be more aggressive, which helps the medical team plan more intensive care [6, 9].

The Future of Treatment

Scientists are now working on “targeted therapies” [2, 11]. Because FLI1-related cancers often have unique markers like ILIRAP that are not found on healthy tissue, researchers are developing treatments—such as immunotherapy—that can specifically hunt down and attack the cancer cells while leaving your healthy cells alone [11]. This is an exciting step forward in making cancer treatment more effective and less damaging to the rest of the body.

References:

1. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162-5.

2. Sankar S, Theisen ER, Bearss J, et al. Reversing EWS-FLI1 transcriptional signature by targeted inhibition of epigenetic machinery. Oncotarget. 2013;4(11):2065-77.

3. Wernig G, Rosenbauer F, Morris SW, et al. The transcription factor FLI1 is a critical regulator of hematopoietic stem cell development. Proc Natl Acad Sci U S A. 2008;105(48):18861-6.

4. Spyropoulos DD, Phin GA, Epps B, et al. The ETS protein Fli-1 is required for the development of megakaryocytes and erythroid cells. Blood. 2000;96(9):3049-55.

5. Messika-Zeitoun D, O’Gara P. Vascular tumors: an update. Curr Treat Options Cardiovasc Med. 2004;6(2):167-75.

6. Mao X, Yang X, Lu W, et al. FLI1 promotes the proliferation and migration of non-small cell lung cancer cells. Exp Ther Med. 2017;14(6):6133-40.

7. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing’s family tumors. Oncogene. 2001;20(40):5747-54.

8. Kochetkov DV, Pospelova TV, Pospelov VA. The role of the transcription factor FLI1 in the regulation of cell proliferation and differentiation. Biochemistry (Mosc). 2018;83(10):1199-211.

9. Ren C, Zhang M, Deng H, et al. Overexpression of FLI1 is associated with poor prognosis in patients with astrocytoma. Int J Clin Exp Pathol. 2015;8(10):13303-9.

10. Hahne JC, Schiefer M, Hahne-Pappas J, et al. Transcription factor ERG and FLI1 in human endothelial cells and vascular tumors. Histol Histopathol. 2005;20(1):161-8.

11. Zhu X, Chen Y, Wang Y, et al. EWS-FLI1-induced overexpression of IL1RAP promotes Ewing sarcoma progression. Cancer Res. 2021;81(13):3628-40.

12. Balamuth NJ, Womer RB. Ewing’s sarcoma. Lancet Oncol. 2010;11(2):184-92.

13. Watson DK, Smyth FE, Thompson DM, et al. The ETS transcription factor family: molecular biology and cancer. Anticancer Res. 1997;17(3A):1501-7.

FAQ’s:

1. What is the FLI1 protein?
FLI1 is a transcription factor encoded by the FLI1 gene, critical for blood cell and vessel development.

2. Which cancers involve FLI1 mutations?
Mutations in the FLI1 gene are specifically known to cause an aggressive tumor called Ewing sarcoma.

3. How is FLI1 detected clinically?
Pathologists identify FLI1 expression using an immunohistochemistry (IHC) test on formalin-fixed, paraffin-embedded tissue samples.

4. What is a positive result?
A positive result is indicated by nuclear staining, with 10% or more cells showing clear positivity.

5. What is the internal control?
Endothelial cells serve as the reliable positive internal control for the FLI1 immunohistochemistry diagnostic assay.

6. Is FLI1 a diagnostic marker?
Yes, it is a gold standard marker for diagnosing angiosarcoma and tumors originating from blood vessels.

7. Does FLI1 impact cancer prognosis?
Overexpression of FLI1 in cancers like astrocytoma and lung cancer often correlates with a poor prognosis.

8. What is the ILIRAP target?
ILIRAP is a direct target of EWS-FLI1, highly expressed in Ewing sarcoma but minimal in normal tissue.

9. Can FLI1 be therapeutically targeted?
Yes, researchers are investigating FLI1 targets as promising surface points for potentially effective new immunotherapy treatments.

10. What is FLI1’s physiological role?
It is vital for maintaining and differentiating hematopoietic stem cells and regulating the process of angiogenesis.